These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26156248)

  • 21. Predictive values of an immunological fecal occult blood test for the diagnosis of colorectal cancer compared using colonoscopy in symptomatic patients in Yaounde (Cameroon).
    Jovanka TU; Wilson NNA; Winnie BN; Paule NM; Paul T; Isabelle DB; Magloire BS
    BMC Gastroenterol; 2024 Jun; 24(1):198. PubMed ID: 38877426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials.
    Bretthauer M; Wieszczy P; Løberg M; Kaminski MF; Werner TF; Helsingen LM; Mori Y; Holme Ø; Adami HO; Kalager M
    JAMA Intern Med; 2023 Nov; 183(11):1196-1203. PubMed ID: 37639247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies to improve repeat fecal occult blood testing cancer screening.
    Davis TC; Arnold CL; Bennett CL; Wolf MS; Reynolds C; Liu D; Rademaker A
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):134-43. PubMed ID: 24192009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations.
    Nadel MR; Berkowitz Z; Klabunde CN; Smith RA; Coughlin SS; White MC
    J Gen Intern Med; 2010 Aug; 25(8):833-9. PubMed ID: 20383599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hub-and-Spoke centralized intervention to optimize colorectal cancer screening and follow-up: A pragmatic, cluster-randomized controlled trial protocol.
    Castañeda SF; Gupta S; Nodora JN; Largaespada V; Roesch SC; Rabin BA; Covin J; Ortwine K; Preciado-Hidalgo Y; Howard N; Halpern MT; Martinez ME
    Contemp Clin Trials; 2023 Nov; 134():107353. PubMed ID: 37802222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomous Artificial Intelligence vs Artificial Intelligence-Assisted Human Optical Diagnosis of Colorectal Polyps: A Randomized Controlled Trial.
    Djinbachian R; Haumesser C; Taghiakbari M; Pohl H; Barkun A; Sidani S; Liu Chen Kiow J; Panzini B; Bouchard S; Deslandres E; Alj A; von Renteln D
    Gastroenterology; 2024 Jul; 167(2):392-399.e2. PubMed ID: 38331204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing.
    Ioannou S; Sutherland K; Sussman DA; Deshpande AR
    BMC Cancer; 2021 Aug; 21(1):966. PubMed ID: 34454457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography.
    Boellaard TN; van der Paardt MP; Eberl S; Hollmann MW; Stoker J
    BMC Gastroenterol; 2011 Nov; 11():128. PubMed ID: 22111658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticipated regret to increase uptake of colorectal cancer screening (ARTICS): A randomised controlled trial.
    O'Carroll RE; Chambers JA; Brownlee L; Libby G; Steele RJ
    Soc Sci Med; 2015 Oct; 142():118-27. PubMed ID: 26301484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of a decision aid for promoting colorectal cancer screening in Spain: a randomized trial.
    Perestelo-Perez L; Rivero-Santana A; Torres-Castaño A; Ramos-Garcia V; Alvarez-Perez Y; Gonzalez-Hernandez N; Buron A; Pignone M; Serrano-Aguilar P
    BMC Med Inform Decis Mak; 2019 Jan; 19(1):8. PubMed ID: 30630487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer screening: the northern trust experience.
    Neely D; Campbell W; Davey P; Rodgers C; McCrory D
    Ulster Med J; 2013 Sep; 82(3):160-3. PubMed ID: 24505151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review.
    Tanadi C; Tandarto K; Stella MM; Sutanto KW; Steffanus M; Tenggara R; Bestari MB
    Rom J Intern Med; 2024 Jun; 62(2):101-123. PubMed ID: 38153878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ColonCancerCheck primary care invitation pilot project: patient perceptions.
    Tinmouth J; Ritvo P; McGregor SE; Patel J; Guglietti C; Levitt CA; Paszat LF; Rabeneck L
    Can Fam Physician; 2013 Dec; 59(12):e541-9. PubMed ID: 24336559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardized Workflows Improve Colonoscopy Follow-Up After Abnormal Fecal Immunochemical Tests in a Safety-Net System.
    Issaka RB; Rachocki C; Huynh MP; Chen E; Somsouk M
    Dig Dis Sci; 2021 Mar; 66(3):768-774. PubMed ID: 32236885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A computerized intervention to promote colorectal cancer screening for underserved populations: theoretical background and algorithm development.
    Greiner KA; Geana MV; Epp A; Watson A; Filippi M; Daley CM; Engelman KK; James AS; Campbell M
    Technol Health Care; 2012; 20(1):25-35. PubMed ID: 22297711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IARC Perspective on Colorectal Cancer Screening.
    Lauby-Secretan B; Vilahur N; Bianchini F; Guha N; Straif K;
    N Engl J Med; 2018 May; 378(18):1734-1740. PubMed ID: 29580179
    [No Abstract]   [Full Text] [Related]  

  • 38. Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study.
    Ruco A; Moineddin R; Sutradhar R; Tinmouth J; Li Q; Rabeneck L; Del Giudice ME; Dubé C; Baxter NN
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):601-608. PubMed ID: 38761808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.
    Brenner A; Howard K; Lewis C; Sheridan S; Crutchfield T; Hawley S; Reuland D; Kistler C; Pignone M
    J Gen Intern Med; 2014 Mar; 29(3):507-13. PubMed ID: 24272830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.
    Chung DC; Gray DM; Singh H; Issaka RB; Raymond VM; Eagle C; Hu S; Chudova DI; Talasaz A; Greenson JK; Sinicrope FA; Gupta S; Grady WM
    N Engl J Med; 2024 Mar; 390(11):973-983. PubMed ID: 38477985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.